Results 121 to 130 of about 4,736,557 (326)
Molecular Oncology, EarlyView.Consensus molecular subtypes (CMS1‐4) have been identified to study colorectal cancer heterogeneity and serve as potential biomarkers. In this study, we developed and evaluated NanoCMSer, a NanoString‐based classifier using 55 genes, optimized for FF and FFPE to facilitate the clinical evaluation of CMS subtyping.
Arezo Torang +10 more
wiley +1 more source
Variable Selection with Random Survival Forest and Bayesian Additive Regression Tree for Survival Data [PDF]
arXiv, 2019 In this paper we utilize a survival analysis methodology incorporating Bayesian additive regression trees to account for nonlinear and additive covariate effects. We compare the performance of Bayesian additive regression trees, Cox proportional hazards and random survival forests models for censored survival data, using simulation studies and survival
arxiv
Red cell survival time in man measured by 50Cr and activation analysis. [PDF]
, 1968 Gary Donaldson +3 more
openalex +1 more source
Molecular Oncology, EarlyView.The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang +3 more
wiley +1 more source
arXiv, 2016 The electronic health record (EHR) provides an unprecedented opportunity to build actionable tools to support physicians at the point of care. In this paper, we investigate survival analysis in the context of EHR data. We introduce deep survival analysis, a hierarchical generative approach to survival analysis.
arxiv
Survival analysis of the optical brightness of GRB host galaxies [PDF]
, 2015 We studied the unbiased optical brightness distribution which was calculated from the survival analysis of host galaxies and its relationship with the Swift GRB data of the host galaxies observed by the Keck telescopes.
Bagoly, Z. +3 more
core +1 more source
Section IV. Statistical Analysis with Special Regard to Survival Rate [PDF]
, 1960 openalex +1 more source
Molecular Oncology, EarlyView.Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou +11 more
wiley +1 more source
Biophysical Interpretation on the Biological Actions of Radiations (II) (On the Examples of the Type-Analysis of the Dose-Survival and the Dose-Effect Curves) [PDF]
, 1961 Yasushi NISHIWAKI
openalex +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, EarlyView.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source